-
Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data
Wednesday, October 6, 2021 - 3:47pm | 218Read More...Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis. The Phase 2 Dose-Ranging study showed clinically significant changes in increases...
-
Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study
Thursday, March 11, 2021 - 10:23am | 362Read More...Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral density). Three-month bone biomarker data analysis showed a significant increase...
-
Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline
Monday, January 29, 2018 - 12:50pm | 439Read More...Radius Health Inc (NASDAQ: RDUS) has multiple catalysts that could drive near-term upside in the shares of the company, according to Morgan Stanley. Radius Health is an integrated biopharma company that specializes in therapies for osteoporosis, oncology and endocrine diseases. The Analyst...
